Table 1 Characteristics of subgroup (by the NanoString assay)
Clinical Features | Number of Cases (%) or value | ||||
|---|---|---|---|---|---|
WNT (N = 14) | SHH (N = 20) | Group 3 (N = 18) | Group 4 (N = 39) | P value | |
Gender | Â | Â | Â | Â | 0.003 |
  M | 3 (21.4%) | 11 (55.0%) | 14 (77.8%) | 28 (71.8%) |  |
  F | 11 (78.6%) | 9 (45.0%) | 4 (22.2%) | 11 (28.2%) |  |
Age (years) | Â | Â | Â | Â | 0.007 |
   ≤ 3 | 1 (7.1%) | 7 (35.0%) | 7 (38.9%) | 3 (7.7%) |  |
  3–18 | 13 (92.9%) | 13 (65.0%) | 11 (61.1%) | 36 (92.3%) |  |
Metastasis at diagnosis | Â | Â | Â | Â | 0.096 |
  Negative | 11 (78.6%) | 14 (70.0%) | 7 (38.9%) | 25 (64.1%) |  |
  Positive | 3 (21.4%) | 6 (30.0%) | 11 (61.1%) | 14 (35.9%) |  |
Tumor location |  |  |  |  |  < 0.001 |
  Midline | 8 (57.1%) | 8 (40.0%) | 18 (100.0%) | 39 (100.0%) |  |
  Hemispheric | 0 (0.0%) | 12 (60.0%) | 0 (0.0%) | 0 (0.0%) |  |
  Peduncle | 6 (42.9%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |  |
Histology | Â | Â | Â | Â | 0.018 |
  Classic | 13 (92.9%) | 5 (25.0%) | 10 (55.6%) | 27 (69.2%) |  |
  MBEN | 0 (0.0%) | 5 (25.0%) | 4 (22.2%) | 5 (12.8%) |  |
  DN | 1 (7.1%) | 4 (20.0%) | 1 (5.6%) | 2 (5.1%) |  |
  LCA | 0 (0.0%) | 6 (30.0%) | 3 (16.7%) | 5 (12.8%) |  |